Marksans Pharma Limited
Symbol: MARKSANS.NS
NSE
162.35
INRMarktpreis heute
22.5480
P/E-Verhältnis
0.8053
PEG-Verhältnis
73.57B
MRK Kapital
- 0.00%
DIV Rendite
Marksans Pharma Limited (MARKSANS-NS) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 27678.4 | 7191.6 | 3466.9 | 2093.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 34038.7 | 3367.2 | 4.3 | 17.2 | |||||||||||||||||||
balance-sheet.row.net-receivables | 8696.08 | 4187.6 | 4115.6 | 2767.3 | |||||||||||||||||||
balance-sheet.row.inventory | 10153.42 | 4847.4 | 4244.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 1029.74 | 526.4 | 185.1 | 118.2 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 47557.64 | 16753 | 12012 | 9022.5 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8581.34 | 3868.9 | 3422.9 | 2540.2 | |||||||||||||||||||
balance-sheet.row.goodwill | 771.91 | 384.9 | 300.3 | 195.9 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1395.4 | 708 | 585.7 | 474.4 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2167.31 | 1092.9 | 885.9 | 670.2 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -6433 | -3332.4 | -62 | 8.4 | |||||||||||||||||||
balance-sheet.row.tax-assets | 6517.3 | 3375.9 | 38.6 | 8 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -13350.95 | 145.7 | 103.7 | 33.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | -2518 | 5150.9 | 4389 | 3260 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 45039.64 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.account-payables | 4309.35 | 2306 | 2000.8 | 1686.6 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1073.1 | 572.6 | 693.4 | 247.8 | |||||||||||||||||||
balance-sheet.row.tax-payables | 667.33 | 252.8 | 173.3 | 300.2 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1267.38 | 656.9 | 414.3 | 93.3 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 121.1 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 321.13 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 376.6 | 112.4 | 543 | 639.3 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1681.51 | 843.3 | 609.1 | 245 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1572.51 | 813.6 | 694.9 | 153.6 | |||||||||||||||||||
balance-sheet.row.total-liab | 8418.8 | 4253.2 | 4171.3 | 3229 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 13274.17 | 13274.2 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 906.32 | 453.2 | 409.3 | 409.3 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 10913.4 | 10913.4 | 5093.1 | 3349.3 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 58687.73 | 4177.4 | 4788.4 | 3355 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -10953.25 | -11366.6 | 1731.9 | 1751.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 72828.37 | 17451.6 | 12022.7 | 8864.9 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 81660.48 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.minority-interest | 413.31 | 199.1 | 207 | 188.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 73241.68 | 17650.7 | 12229.7 | 9053.5 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 81660.48 | - | - | - | |||||||||||||||||||
Total Investments | 27605.7 | 34.8 | 26.1 | 25.6 | |||||||||||||||||||
balance-sheet.row.total-debt | 2340.48 | 1229.5 | 1107.8 | 341 | |||||||||||||||||||
balance-sheet.row.net-debt | 8700.78 | -2594.9 | -2354.8 | -1752.8 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3181.21 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1114.7 | -1107 | -1500.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | -275.2 | -1039.3 | -367.4 | |||||||||||||||||
cash-flows.row.inventory | 0 | -448.5 | -178.5 | -1624.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 224.2 | 184.9 | 417.8 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -615.2 | -74.1 | 74.1 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -3181.21 | -406.3 | -823.3 | -95.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1343.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -266.1 | 0.3 | 5.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1897.7 | -1.5 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2163.8 | -0.3 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -2055.8 | 47.9 | 10.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2592.1 | -416.9 | -449 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2295.4 | -225.5 | -1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2747.1 | 911.5 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -451.7 | -225.5 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -101.7 | -105.8 | -40.9 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2080 | 440.4 | -110.9 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1978.3 | 795.1 | -152.9 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -1428.6 | -1 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 1343.16 | 1760.3 | 1370.8 | 1185.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 21580.94 | 3824.4 | 3492.7 | 2122.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 20237.78 | 2064.1 | 2121.8 | 937.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 1343.16 | 2374.1 | 992.6 | 1787.4 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.free-cash-flow | 1343.16 | 1837.8 | 529.3 | 1323.2 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 21033.72 | 18521.4 | 14801.2 | 13683.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 10121.39 | 9213.6 | 7480.2 | 6186 | |||||||||||||||||||
income-statement-row.row.gross-profit | 10912.33 | 9307.8 | 7321.1 | 7497.8 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 283.89 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 6999.05 | 6433.1 | 5153.7 | 4310.6 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 17120.44 | 15646.7 | 12633.9 | 10496.6 | |||||||||||||||||||
income-statement-row.row.interest-income | 158.31 | 59.4 | 59.7 | 11.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 5033.87 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 4261.33 | 2877.3 | 2141 | 3092.2 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 4274.26 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 1074.63 | 723.3 | 607 | 636.3 | |||||||||||||||||||
income-statement-row.row.net-income | 3173.43 | 2663.1 | 1845.7 | 2385.4 |
Häufig gestellte Frage
Wie hoch ist die Marksans Pharma Limited (MARKSANS.NS) Gesamtvermögen?
Marksans Pharma Limited (MARKSANS.NS) Gesamtvermögen ist 21903890000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 11173630000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.519.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 2.964.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.151.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.203.
Was ist der Marksans Pharma Limited (MARKSANS.NS) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 2663080000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1229450000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 6433130000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist -6611350000.000.